check_circleStudy Completed

Solid Tumors Harboring NTRK Fusion

Study in healthy adult male participants to gather information how the human body absorbs, distributes and excretes the study drug selitrectinib including the effect of the interaction of food with the study drug on the human body

Trial purpose

The researchers in this study want to gather information in healthy adult male participants about how the human body absorbs, distributes and excretes the drug selitrectinib including the effect of the interaction of food with the study drug on the human body. Selitrectinib is a new drug under development for the treatment of patients with solid tumor caused by a genetic abnormality known as an NTRK gene fusion which cannot be cured by currently available treatment options or has spread to other parts of the body. The drug blocks the action of the NTRK gene fusion and prevents the activation of certain proteins (TRK fusion proteins), which can cause cancer cells to multiply and form a tumor. Researchers also want to find out if the participants have any medical problems during this study.
Participants in this study will receive the study drug twice with at least 6 days in between. The study drug will be taken orally as a liquid before or after meal. Observation will last for up to 8 weeks, and blood samples will be taken from the participants to measure the blood levels of the study drug.

Key Participants Requirements

Sex

Male

Age

18 - 45 Years

Trial summary

Enrollment Goal
24
Trial Dates
February 2020 - November 2020
Phase
Phase 1
Could I Receive a placebo
No
Products
selitrectinib (LOXO-195, BAY2731954)
Accepts Healthy Volunteer
Yes

Where to participate

StatusInstitutionLocation
Completed
CRS Clinical-Research-Services Mannheim GmbHMannheim, 68167, Germany

Primary Outcome

  • Maximum concentration of selitrectinib in plasma in fasted state (Cmax_fasted)
    date_rangeTime Frame:
    Up to 3 days
  • Area under the concentration-time curve of selitrectinib in plasma from time 0 to 24 hours in fasted state (AUC(0-24)_fasted)
    date_rangeTime Frame:
    Up to 1 day
  • Area under the concentration-time curve of selitrectinib in plasma from time 0 to infinity in fasted state (AUC_fasted)
    date_rangeTime Frame:
    Up to 3 days
  • Maximum concentration of selitrectinib in plasma in fed state (Cmax_fed)
    date_rangeTime Frame:
    Up to 3 days
  • Area under the concentration-time curve of selitrectinib in plasma from time 0 to 24 hours in fed state (AUC(0-24)_fed)
    date_rangeTime Frame:
    Up to 1 days
  • Area under the concentration-time curve of selitrectinib in plasma from time 0 to infinity in fed state (AUC_fed)
    date_rangeTime Frame:
    Up to 3 days

Secondary Outcome

  • Number of participants with treatment-emergent adverse events (TEAEs)
    date_rangeTime Frame:
    Up to 23 weeks

Trial design

An open-label, non-randomized, Phase I study to evaluate the pharmacokinetics of selitrectinib (BAY 2731954) and food effects in healthy adult male participants
Trial Type
Interventional
Intervention Type
Drug
Trial Purpose
Basic Science
Allocation
Non-randomized
Blinding
N/A
Assignment
Sequential Assignment
Trial Arms
3